N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
First Claim
Patent Images
1. A compound of formula I and enantiomers, diastereomers and pharmaceutically acceptable salts thereof whereinR is alkyl;
- R1 is hydrogen or alkyl;
X is NR2 or CHNR2R3;
R2 and R3 are each independently hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl; and
n is 0, 1, 2 or 3.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention describes compounds of formula I:
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.
The formula I compounds are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimer'"'"'s disease, chemotherapy-induced alopecia, and cardiovascular disease.
31 Citations
59 Claims
-
1. A compound of formula I
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof wherein R is alkyl; -
R1 is hydrogen or alkyl;
X is NR2 or CHNR2R3;
R2 and R3 are each independently hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl; and
n is 0, 1, 2 or 3. - View Dependent Claims (2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)
R is alkyl; R1 is hydrogen;
X is NR2 or CHNR2R3;
R2 and R3 are each independently hydrogen, alkyl, substituted alkyl or cycloalkyl; and
n is 2.
-
-
3. The compound according to claim 1 of formula Ia
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof wherein R2 is hydrogen, alkyl, substituted alkyl or cycloalkyl. -
4. The compound according to claim 1 of formula Ib
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof wherein R2 is hydrogen, alkyl, substituted alkyl or cycloalkyl. -
5. The compound according to claim 1 of formula Ic
and enantiomers, diasteromers and pharmaceutically acceptable salts thereof wherein R2 and R3 are each independently hydrogen, alkyl, substituted alkyl or cycloalkyl. -
6. The compound according to claim 1 selected from the group consisting of
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide; -
(±
)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide;
(±
)-1-(2,3-dihydroxypropyl)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-1-(1-methylethyl)-4-piperidinecarboxamide;
1-cyclopropyl-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-1-(2-hydroxyethyl)-4-piperidinecarboxamide;
(R)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide;
(S)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide;
cis-4-amino-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]cyclohexylcarboxamide; and
trans-4-amino-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]cyclohexylcarboxamide; and
pharmaceutically acceptable salts thereof.
-
-
13. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.
-
14. A pharmaceutical composition which comprises a compound of claim 1 in combination with a pharmaceutically acceptable carrier and an anti-cancer agent formulated as a fixed dose.
-
15. A pharmaceutical composition which comprises a compound of claim 1 in combination with a pharmaceutically acceptable carrier and a modulator of p53 transactivation formulated as a fixed dose.
-
16. A method for modulating apoptosis which comprises administering to a mammalian specie in need thereof an effective apoptosis modulating amount of a compound of claim 1.
-
17. A method for inhibiting protein kinases which comprises administering to a mammalian specie in need thereof an effective protein kinase inhibiting amount of a compound of claim 1.
-
18. A method for inhibiting cyclin dependent kinases which comprises administering to a mammalian specie in need thereof an effective cyclin dependent kinase inhibiting amount of a compound of claim 1.
-
19. A method for inhibiting cdc2 (cdk1) which comprises administering to a mammalian specie in need thereof an effective cdc2 inhibiting amount of a compound of claim 1.
-
20. A method for inhibiting cdk2 which comprises administering to a mammalian specie in need thereof an effective cdk2 inhibiting amount of a compound of claim 1.
-
21. A method for inhibiting cdk3 which comprises administering to a mammalian specie in need thereof an effective cdk3 inhibiting amount of a compound of claim 1.
-
22. A method for inhibiting cdk4 which comprises administering to a mammalian specie in need thereof an effective cdk4 inhibiting amount of a compound of claim 1.
-
23. A method for inhibiting cdk5 which comprises administering to a mammalian specie in need thereof an effective cdk5 inhibiting amount of a compound of claim 1.
-
24. A method for inhibiting cdk6 which comprises administering to a mammalian specie in need thereof an effective cdk6 inhibiting amount of a compound of claim 1.
-
25. A method for inhibiting cdk7 which comprises administering to a mammalian specie in need thereof an effective cdk7 inhibiting amount of a compound of claim 1.
-
26. A method for inhibiting cdk8 which comprises administering to a mammalian specie in need thereof an effective cdk8 inhibiting amount of a compound of claim 1.
-
27. A method for treating proliferative diseases which comprises administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 13.
-
28. A method for treating cancer which comprises administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 13.
-
29. A method for treating inflammation, inflammatory bowel disease or transplantation rejection which comprises administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 13.
-
30. A method for treating arthritis which comprises administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 13.
-
31. A method for treating proliferative diseases which comprises administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 14.
-
32. A method for treating cancer which comprises administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 14.
-
33. A method for treating proliferative diseases which comprises administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 15.
-
34. A method for treating cancer which comprises administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 15.
-
35. A method for the treatment of a cyclin dependent kinase-associated disorder which comprises administering to a subject in need thereof an amount effective therefor of at least one compound of claim 1.
-
36. A method for treating chemotherapy-induced alopecia, chemotherapy-induced thrombocytopenia, chemotherapy-induced leukopenia or mucocitis which comprises administering to a mammalian specie in need thereof a therapeutically effective amount of a compound of claim 1.
-
37. The compound of claim 1 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
38. The compound of claim 2 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
39. The compound of claim 3 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
40. The compound of claim 4 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
41. The compound of claim 5 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
42. The compound of claim 6 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
49. The pharmaceutical composition of claim 13 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
50. The pharmaceutical composition of claim 14 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
51. The pharmaceutical composition of claim 15 wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
52. The method of claim 17 wherein said pharmaceutically acceptable salt of said compound is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
53. The method of claim 18 wherein said pharmaceutically acceptable salt of said compound is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
54. The method of claim 20 wherein said pharmaceutically acceptable salt of said compound is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
55. The method of claim 27 wherein said pharmaceutically acceptable salt of said compound is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
56. The method of claim 28 wherein said pharmaceutically acceptable salt of said compound is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
57. The method of claim 31 wherein said pharmaceutically acceptable salt of said compound is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
58. The method of claim 32 wherein said pharmaceutically acceptable salt of said compound is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
-
59. The method of claim 36 wherein said pharmaceutically acceptable salt of said compound is selected from the group consisting of hydrochloride, dihydrochloride, sulfate, trifluoroacetate, mixture of trifluoroacetate and hydrochloride, tartrate, fumarate, succinate, maleate, citrate, methanesulfonate, bromate and iodate salts.
- 7. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide and pharmaceutically acceptable salts thereof.
-
8. (±
- )-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide and pharmaceutically acceptable salts thereof.
- View Dependent Claims (44)
- 9. (R)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide and pharmaceutically acceptable salts thereof.
- 10. (S)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide and pharmaceutically salts thereof.
- 11. cis-4-amino-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]cyclohexylcarboxamide and pharmaceutically acceptable salts thereof.
- 12. trans-4-amino-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]cyclohexylcarboxamide and pharmaceutically acceptable salts thereof.
Specification